â सà¥à¤µà¤¾à¤¸à¥à¤¥à¥à¤¯ · दवाà¤à¤
ð यह केवल जानकारी है, प्रिस्क्रिप्शन नहीं। कोई भी दवा लेने से पहले डॉक्टर या फार्मासिस्ट से सलाह लें। ओवरडोज़/विषाक्तता पर 102 पर कॉल करें।
Common side effects: The following adverse reactions associated with the use of rifampin were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Pregnancy (label summary):, Teratogenic Effects Rifampin has been shown to be teratogenic in rodents. There are no adequate and well-controlled studies of rifampin in pregnant women. Rifampin has been reported to cross the placental barrier and appear in cord blood. Breastfeeding (label summary): Nursing Mothers Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. General information only, not medical advice and not a prescription. No doses are given. Always consult a doctor or pharmacist before starting, stopping or changing any medicine, especially in pregnancy, breastfeeding, children, older age or with other medicines. DigiNepal SI द्वारा उद्धृत स्रोतों से तैयार · सामान्य जानकारी, निदान नहीं · स्वास्थ्यकर्मी से सलाह लें
सà¥à¤°à¥à¤¤: FDA SPL label (openFDA/DailyMed); RxNorm (NLM)
The following adverse reactions associated with the use of rifampin were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Pregnancy (label summary):, Teratogenic Effects Rifampin has been shown to be teratogenic in rodents. There are no adequate and well-controlled studies of rifampin in pregnant women. Rifampin has been reported to cross the placental barrier and appear in cord blood. Breastfeeding (label summary): Nursing Mothers Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. General information only, not medical advice and not a prescription. No doses are given. Always consult a doctor or pharmacist before starting, stopping or changing any medicine, especially in pregnancy, breastfeeding, children, older age or with other medicines.
à¤à¤µà¤°à¤¡à¥à¤à¤¼/विषाà¤à¥à¤¤à¤¤à¤¾ à¤à¥ à¤à¤¶à¤à¤à¤¾ पर ठà¤à¥ 102 पर à¤à¥à¤² à¤à¤°à¥à¤à¥¤
ð 102सà¥à¤°à¥à¤¤: FDA SPL label (openFDA/DailyMed); RxNorm (NLM)
RxNorm / DailyMed / FDA / MedlinePlus (NLM)